Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients
Phase 2 Unknown
30 enrolled
BELLA
Phase 2 Unknown
31 enrolled
The Efficacy and Safety of Lcaritin Combined With Bevacizumab and FOLFIRI in Treatment of Liver Metastases From Colorectal Cancer
Phase 4 Unknown
20 enrolled
HCC
Unknown
100 enrolled
Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
Phase 2 Unknown
40 enrolled
Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer
Unknown
30 enrolled
Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy
Phase 2 Unknown
35 enrolled
FUTURE-SUPER
Phase 2 Unknown
139 enrolled
DEBIRI
Phase NA Unknown
39 enrolled
Hepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver Transplantation
Phase 2 Unknown
25 enrolled
COBRA
Unknown
121 enrolled
AIO-KRK-0116
Phase 2 Unknown
109 enrolled
REVOLUTION
Phase 2 Unknown
200 enrolled
Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
Phase 2 Unknown
33 enrolled
ATHENA
Phase 2 Unknown
33 enrolled
POCHI
Phase 2 Unknown
55 enrolled
SIRTCI
Phase 2 Unknown
52 enrolled
BEACON
Phase 2 Unknown
30 enrolled
Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer
Phase 3 Unknown
198 enrolled
Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
Phase 2 Unknown
48 enrolled
Calizumab Combined With Bevacizumab and Capecitabine in the Treatment of Head and Neck Squamous Cell Carcinoma
Phase 2 Unknown
22 enrolled
SELENIUM
Phase 3 Unknown
68 enrolled
SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer
Phase 2 Unknown
90 enrolled
HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial
Phase 2 Unknown
40 enrolled
The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab
Phase 2 Unknown
44 enrolled
Efficacy and Safety of SCAI of Bevacizumab Combined With IC of Tislelizumab in the Treatment of Recurrent Glioblastoma.
Phase NA Unknown
36 enrolled
Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC
Phase 3 Unknown
228 enrolled
Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer
Phase 2 Unknown
20 enrolled
Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer
Phase 3 Unknown
60 enrolled
Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer
Phase 2 Unknown
30 enrolled
MITO16/MANGO-2
Phase 4 Unknown
400 enrolled
MITO16MANGO2b
Phase 3 Unknown
406 enrolled
BEVERLY
Phase 3 Unknown
200 enrolled
Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma
Phase 2 Unknown
30 enrolled
MiST
Phase 2 Unknown
186 enrolled
RE-GEND
Phase 3 Unknown
146 enrolled
Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T
Phase 2 Unknown
30 enrolled
Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer
Phase 2 Unknown
87 enrolled
SLURP
Phase 2 Unknown
25 enrolled
Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study
Phase 2 Unknown
33 enrolled
Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Non-squamous NSCLC After First-line Treatment
Phase 2 Unknown
45 enrolled
Microbiome Immunotherapy Toxicity and Response Evaluation
Unknown
1,800 enrolled
Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer
Phase 2 Unknown
37 enrolled
Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer
Phase 2 Unknown
40 enrolled
SPBPDC
Phase 3 Unknown
60 enrolled
Low-dose Bevacizumab With HSRT vs BVZ Alone for GBM at First Recurrence
Phase 2 Unknown
42 enrolled
Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases
Phase 2 Unknown
12 enrolled
BOLD
Phase 2 Unknown
74 enrolled
Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme
Phase 1 Unknown
30 enrolled
Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer
Phase 2 Unknown
17 enrolled